Merck cuts sales forecast for Zocor
Article Abstract:
The author examines Merck and Company?s announcement that it will be force to revise earlier 2003 sales projections on its popular cholesterol fighting drug Zocor. Topics include sales levels, profit margins, and competition.
Publisher: Philadelphia Newspapers, Inc.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2003
Business losses, Merck & Company Inc.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Enterprise of old drugs, old friends
Article Abstract:
The author examines the growing success and the story behind the founding of Endo Pharmaceuticals Inc. Topics include industry- related background of company founders, marketing of Lidoderm, and business growth and profits.
Publisher: Philadelphia Newspapers, Inc.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2003
Product information, Marketing procedures, Executive changes & profiles, Officials and employees, Marketing, Company marketing practices, ENDO Pharmaceuticals Inc., Lidoderm (Medication)
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: United States, Pharmaceutical industry, Finance, Profit, Profits, Company financing
Similar abstracts:
- Abstracts: Crown Cork cutting 1,150 jobs. Crown Cork holds dividend. Crown Cork raises reserve on asbestos claims
- Abstracts: DuPont reels from high energy prices. Advanta warns of lower profits. Stocks' 3d-quarter drop felt here
- Abstracts: Settlement is reached by Wyeth and U.S. FDA seizes Wyeth drugs, citing quality standards. Aramark Tower sale postponed
- Abstracts: Settlement is reached by Wyeth and U.S. Drug firms using coupons in bid to retain customers
- Abstracts: Earnings warnings on the rise. Rohm & Haas to make cutbacks
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.